{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:50:32Z","timestamp":1786647032667,"version":"build-2736575974"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,12]]},"DOI":"10.7759\/cureus.62247","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T14:18:10Z","timestamp":1718201890000},"source":"Crossref","is-referenced-by-count":3,"title":["Anakinra in Pyogenic Arthritis, Acne, Pyoderma Gangrenosum, and Suppurative Hidradenitis (PAPASH) Spectrum Disorder: A Case Report and Literature Review"],"prefix":"10.7759","author":[{"given":"Anam","family":"Ahmad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.2907","article-title":"Pyogenic arthritis, pyoderma gangrenosum, acne, and hidradenitis suppurativa (PAPASH): a new autoinflammatory syndrome associated with a novel mutation of the PSTPIP1 gene","volume":"149","author":"Marzano AV","year":"2013","unstructured":"Marzano AV, Trevisan V, Gattorno M, Ceccherini I, De Simone C, Crosti C. Pyogenic arthritis, pyoderma gangrenosum, acne, and hidradenitis suppurativa (PAPASH): a new autoinflammatory syndrome associated with a novel mutation of the PSTPIP1 gene. JAMA Dermatol. 2013, 149:762-4. 10.1001\/jamadermatol.2013.2907","journal-title":"JAMA Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0149-1","article-title":"Hidradenitis suppurativa","volume":"6","author":"Sabat R","year":"2020","unstructured":"Sabat R, Jemec GB, Matusiak \u0141, Kimball AB, Prens E, Wolk K. Hidradenitis suppurativa. Nat Rev Dis Primers. 2020, 6:18. 10.1038\/s41572-020-0149-1","journal-title":"Nat Rev Dis Primers"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0213-x","article-title":"Pyoderma gangrenosum","volume":"6","author":"Maverakis E","year":"2020","unstructured":"Maverakis E, Marzano AV, Le ST, et al.. Pyoderma gangrenosum. Nat Rev Dis Primers. 2020, 6:81. 10.1038\/s41572-020-0213-x","journal-title":"Nat Rev Dis Primers"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2023.12.004","article-title":"Hidradenitis suppurativa-related autoinflammatory syndromes: an updated review on the clinics, genetics, and treatment of pyoderma gangrenosum, acne and suppurative hidradenitis (PASH), pyogenic arthritis, pyoderma gangrenosum, acne and suppurative hidradenitis (PAPASH), synovitis, acne, pustulosis, hyperostosis and osteitis (SAPHO), and rarer forms","volume":"42","author":"Maronese CA","year":"2024","unstructured":"Maronese CA, Moltrasio C, Marzano AV. Hidradenitis suppurativa-related autoinflammatory syndromes: an updated review on the clinics, genetics, and treatment of pyoderma gangrenosum, acne and suppurative hidradenitis (PASH), pyogenic arthritis, pyoderma gangrenosum, acne and suppurative hidradenitis (PAPASH), synovitis, acne, pustulosis, hyperostosis and osteitis (SAPHO), and rarer forms. Dermatol Clin. 2024, 42:247-65. 10.1016\/j.det.2023.12.004","journal-title":"Dermatol Clin"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2020.10.016","article-title":"PASH, PAPASH, PsAPASH, and PASS: the autoinflammatory syndromes of hidradenitis suppurativa","volume":"39","author":"Garcovich S","year":"2021","unstructured":"Garcovich S, Genovese G, Moltrasio C, Malvaso D, Marzano AV. PASH, PAPASH, PsAPASH, and PASS: the autoinflammatory syndromes of hidradenitis suppurativa. Clin Dermatol. 2021, 39:240-7. 10.1016\/j.clindermatol.2020.10.016","journal-title":"Clin Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.23736\/S0392-0488.20.06629-8","article-title":"PAPA spectrum disorders","volume":"155","author":"Genovese G","year":"2020","unstructured":"Genovese G, Moltrasio C, Garcovich S, Marzano AV. PAPA spectrum disorders. G Ital Dermatol Venereol. 2020, 155:542-50. 10.23736\/S0392-0488.20.06629-8","journal-title":"G Ital Dermatol Venereol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12631","article-title":"Pyoderma gangrenosum, acne, psoriasis, arthritis and suppurative hidradenitis (PAPASH)-syndrome: a new entity within the spectrum of autoinflammatory syndromes?","volume":"30","author":"Garzorz N","year":"2016","unstructured":"Garzorz N, Papanagiotou V, Atenhan A, et al.. Pyoderma gangrenosum, acne, psoriasis, arthritis and suppurative hidradenitis (PAPASH)-syndrome: a new entity within the spectrum of autoinflammatory syndromes?. J Eur Acad Dermatol Venereol. 2016, 30:141-3. 10.1111\/jdv.12631","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-017-0265-1","article-title":"PAPA, PASH and PAPASH syndromes: pathophysiology, presentation and treatment","volume":"18","author":"Cugno M","year":"2017","unstructured":"Cugno M, Borghi A, Marzano AV. PAPA, PASH and PAPASH syndromes: pathophysiology, presentation and treatment. Am J Clin Dermatol. 2017, 18:555-62. 10.1007\/s40257-017-0265-1","journal-title":"Am J Clin Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14383","article-title":"PSTPIP1 gene mutation in a pyoderma gangrenosum, acne and suppurative hidradenitis (PASH) syndrome","volume":"175","author":"Calder\u00f3n-Castrat X","year":"2016","unstructured":"Calder\u00f3n-Castrat X, Bancalari-D\u00edaz D, Rom\u00e1n-Curto C, et al.. PSTPIP1 gene mutation in a pyoderma gangrenosum, acne and suppurative hidradenitis (PASH) syndrome. Br J Dermatol. 2016, 175:194-8. 10.1111\/bjd.14383","journal-title":"Br J Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.074815","article-title":"Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial","volume":"55","author":"Brooklyn TN","year":"2006","unstructured":"Brooklyn TN, Dunnill MG, Shetty A, et al.. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut. 2006, 55:505-9. 10.1136\/gut.2005.074815","journal-title":"Gut"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball AB","year":"2016","unstructured":"Kimball AB, Okun MM, Williams DA, et al.. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016, 375:422-34. 10.1056\/NEJMoa1504370","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.3903","article-title":"Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized clinical trial","volume":"152","author":"Tzanetakou V","year":"2016","unstructured":"Tzanetakou V, Kanni T, Giatrakou S, et al.. Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized clinical trial. JAMA Dermatol. 2016, 152:52-9. 10.1001\/jamadermatol.2015.3903","journal-title":"JAMA Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14037","article-title":"Canakinumab in adults with steroid-refractory pyoderma gangrenosum","volume":"173","author":"Kolios AG","year":"2015","unstructured":"Kolios AG, Maul JT, Meier B, et al.. Canakinumab in adults with steroid-refractory pyoderma gangrenosum. Br J Dermatol. 2015, 173:1216-23. 10.1111\/bjd.14037","journal-title":"Br J Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.52100.2","article-title":"Case report: PsAPSASH syndrome: an alternative phenotype of syndromic hidradenitis suppurativa treated with the IL-17A inhibitor secukinumab","volume":"10","author":"Nikolakis G","year":"2021","unstructured":"Nikolakis G, Kreibich K, Vaiopoulos A, Kaleta K, Talas J, Becker M, Zouboulis CC. Case report: PsAPSASH syndrome: an alternative phenotype of syndromic hidradenitis suppurativa treated with the IL-17A inhibitor secukinumab. F1000Res. 2021, 10:381. 10.12688\/f1000research.52100.2","journal-title":"F1000Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16677","article-title":"Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life","volume":"35","author":"Nguyen TV","year":"2021","unstructured":"Nguyen TV, Damiani G, Orenstein LAV, Hamzavi I, Jemec GB. Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life. J Eur Acad Dermatol Venereol. 2021, 35:50-61. 10.1111\/jdv.16677","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/261965-anakinra-in-pyogenic-arthritis-acne-pyoderma-gangrenosum-and-suppurative-hidradenitis-papash-spectrum-disorder-a-case-report-and-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T14:18:13Z","timestamp":1718201893000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/261965-anakinra-in-pyogenic-arthritis-acne-pyoderma-gangrenosum-and-suppurative-hidradenitis-papash-spectrum-disorder-a-case-report-and-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,12]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.62247","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,12]]}}}